JPWO2021195017A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021195017A5 JPWO2021195017A5 JP2022548517A JP2022548517A JPWO2021195017A5 JP WO2021195017 A5 JPWO2021195017 A5 JP WO2021195017A5 JP 2022548517 A JP2022548517 A JP 2022548517A JP 2022548517 A JP2022548517 A JP 2022548517A JP WO2021195017 A5 JPWO2021195017 A5 JP WO2021195017A5
- Authority
- JP
- Japan
- Prior art keywords
- vapor
- iodine
- composition
- aqueous solution
- article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 19
- 229910052740 iodine Inorganic materials 0.000 claims 19
- 239000011630 iodine Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 13
- 239000007864 aqueous solution Substances 0.000 claims 11
- 230000000241 respiratory effect Effects 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 8
- 244000052769 pathogen Species 0.000 claims 8
- 230000001717 pathogenic effect Effects 0.000 claims 8
- 150000008040 ionic compounds Chemical class 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 238000010438 heat treatment Methods 0.000 claims 4
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 229920000153 Povidone-iodine Polymers 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960002418 ivermectin Drugs 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 229960001621 povidone-iodine Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Claims (21)
(a)前記蒸気は、pHが7.0~10.0の水溶液を、摂氏35~110度(°C)の温度まで加温することによって生成され、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含み、
(b)前記投与は、1日当たり24時間以下であり、
(c)前記患者の気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、組成物。 1. A composition comprising a vapor for administration to the respiratory tract of a subject infected with a respiratory pathogen, comprising:
(a) the vapor is generated by heating an aqueous solution having a pH of 7.0 to 10.0 to a temperature of 35 to 110 degrees Celsius (°C), the aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5 to 10 ppm;
(b) said administration is for 24 hours or less per day ;
(c) a composition wherein the total iodine delivered to the patient's airway does not exceed 16 mg/kg of body weight per day .
pHが7.0~10.0の水溶液が入れられた容器であって、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含む、容器と、
前記容器の中の前記水溶液を摂氏35~110度(°C)の温度まで加温し、これによって蒸気を生成するように構成された加熱要素と、
前記蒸気が呼吸器病原体に感染した対象の気道に到達するように前記蒸気を供給するために構成された人工呼吸器と、を含み、
ここで、前記人工呼吸器は、1日当たり24時間以下、前記蒸気を投与するために構成され、前記気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、システム。 1. A system for treating a subject infected with a respiratory pathogen, comprising:
a container containing an aqueous solution having a pH of 7.0 to 10.0, the aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5 to 10 ppm;
a heating element configured to heat the aqueous solution in the container to a temperature between 35 and 110 degrees Celsius (°C), thereby generating steam;
a ventilator configured to deliver the vapor such that the vapor reaches the airways of a subject infected with a respiratory pathogen;
wherein the ventilator is configured to administer the vapor for no more than 24 hours per day, and wherein the total iodine delivered to the airways does not exceed 16 mg/kg body weight per day.
(a)pHが7.0~10.0の水溶液を、摂氏35~110度(°C)の温度まで加温し、これによって蒸気を生成する工程であって、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含む、工程と、(a) heating an aqueous solution having a pH of 7.0-10.0 to a temperature of 35-110 degrees Celsius (°C), thereby producing steam, said aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5-10 ppm;
(b)前記蒸気を前記対象の気道に1日当たり24時間以下投与する工程であって、ここで、前記気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、工程と(b) administering the vapor to the subject's airway for no more than 24 hours per day, wherein the total iodine delivered to the airway does not exceed 16 mg/kg body weight per day;
を含む、方法。A method comprising:
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062993085P | 2020-03-23 | 2020-03-23 | |
US62/993,085 | 2020-03-23 | ||
US202063026122P | 2020-05-17 | 2020-05-17 | |
US63/026,122 | 2020-05-17 | ||
PCT/US2021/023574 WO2021195017A1 (en) | 2020-03-23 | 2021-03-23 | Iodine compounds for treating respiratory pathogens |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023520289A JP2023520289A (en) | 2023-05-17 |
JPWO2021195017A5 true JPWO2021195017A5 (en) | 2024-04-04 |
Family
ID=76584294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022548517A Pending JP2023520289A (en) | 2020-03-23 | 2021-03-23 | Iodinated compounds for treating respiratory pathogens |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230013142A1 (en) |
EP (1) | EP4125814A1 (en) |
JP (1) | JP2023520289A (en) |
CN (1) | CN115551477A (en) |
CA (1) | CA3169607A1 (en) |
IL (1) | IL275909B (en) |
MX (1) | MX2022010938A (en) |
WO (1) | WO2021195017A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023118979A1 (en) * | 2021-12-22 | 2023-06-29 | Novo Integrated Sciences Inc. | System and method for antibody activators in an aqueous iodine solution |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5038769A (en) * | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
US8303994B2 (en) * | 2006-06-22 | 2012-11-06 | Jack Howard Kessler | Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells |
WO2019009630A1 (en) * | 2017-07-04 | 2019-01-10 | 김대황 | Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof |
-
2020
- 2020-07-07 IL IL275909A patent/IL275909B/en active IP Right Grant
-
2021
- 2021-03-23 JP JP2022548517A patent/JP2023520289A/en active Pending
- 2021-03-23 EP EP21719765.6A patent/EP4125814A1/en active Pending
- 2021-03-23 CN CN202180017161.XA patent/CN115551477A/en active Pending
- 2021-03-23 CA CA3169607A patent/CA3169607A1/en active Granted
- 2021-03-23 MX MX2022010938A patent/MX2022010938A/en unknown
- 2021-03-23 WO PCT/US2021/023574 patent/WO2021195017A1/en unknown
-
2022
- 2022-08-24 US US17/821,895 patent/US20230013142A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6651655B1 (en) | Inhaled vaccines | |
US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
US20080078382A1 (en) | Methods and Systems of Delivering Medication Via Inhalation | |
EP1902742A1 (en) | Methods and systems of delivering medication via inhalation | |
CN101553210A (en) | Methods and systems of delivering medication via inhalation | |
EA022840B1 (en) | Pharmaceutical composition, kit, use thereof and method for prophylactics and treatment of a symptom, condition or disease associated with infection by an influenza virus | |
CN105250245A (en) | Atomized inhalant for treating respiratory system diseases | |
CA3180854A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
Levin et al. | Status asthmaticus and pancuronium bromide | |
JP2022019937A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
US20230013142A1 (en) | Iodine compounds for treating respiratory pathogens | |
JPWO2021195017A5 (en) | ||
JP6628449B1 (en) | Composition for controlling or reducing obstructive airway disease | |
WO1999001138A1 (en) | A pharmaceutical formulation of uridine triphosphate suitable for administration in a small volume | |
US11278688B2 (en) | Inhaling device for heavy metal salts and a method of use thereof for medical treatment | |
US20130123364A1 (en) | N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs | |
CA3169607C (en) | Iodine compounds for treating respiratory pathogens | |
Fong et al. | Inhalation devices for asthma. Choosing the right one could make all the difference. | |
Almukhambetova et al. | Nebulising therapy of bronchial asthma attacks | |
AU2020444401A1 (en) | Pharmaceutical composition of chlorine for treatment of respiratory viral infection | |
Matthys | Nebulizer possibilities and limitations | |
TW505517B (en) | Novel pharmaceutical compositions of uridine triphosphate | |
WO2023083850A1 (en) | Medicament for inhalation or breathing, and inhaler or breathing device comprising same | |
Li et al. | 11 Inhalation Therapy in the Intensive Care Unit | |
RU2143264C1 (en) | Method of treatment of patients with tracheitis |